Abstract:The past year has offered significant advancements in the field of non–small cell lung cancer (NSCLC), both in the early and advanced disease settings. The identification of guideline‐recommended actionable targets has provided the foundation for developing multiple new therapeutic agents. There has been a focus on developing drugs designed to overcome acquired resistance, a limitation of tyrosine kinase inhibitor–based therapy in lung cancer. In addition, there is an emerging trend toward combination therapies for patients in the first‐line setting with the goal of preventing or delaying resistance. Another promising area of development has been the use of antibody–drug conjugates, where there are the initial reports of central nervous system efficacy and activity in patients with genomic alterations. Over the past year, numerous publications and presentations have highlighted multiple therapeutic advances, offering new treatment options for patients with NSCLC. The focus of this review is to summarize the most impactful findings, emphasizing their significance in the evolving treatment landscape for NSCLC. Several landmark trials in lung cancer with practice‐changing clinical implications have been presented and published in 2023. This article reviews a selection of these trials as they relate to early and advanced‐stage oncogene‐driven lung cancer. The ADAURA and ALINA trials, in which targeted therapy given in the adjuvant setting has demonstrated improved clinical outcomes, are reviewed. In the advanced‐stage setting, recent trials in the context of specific oncogene drivers are reviewed, including EGFR, ALK, ROS1, RET, ERBB2 (HER2), BRAF, MET exon 14 skipping (METex14), and KRAS alterations. Also discussed are the results of several trials that have evaluated the use of combination therapies and resistance‐mechanism agnostic treatment strategies. Plain Language Summary Targeted therapy plays an important role for patients with early and advanced‐stage non–small cell lung cancer carrying specific genetic alterations. New strategies that combine multiple therapies are now being studied in randomized clinical trials, with the goal of enhancing the effectiveness of targeted therapy for patients with advanced lung cancer.

New Trends of Advanced Non-Small Cell Lung Cancer Therapy

Advances in Diagnosis and Treatment of HER2-positive Non-small Cell Lung Cancer

New progress in immunotherapy of lung cancer

Recent progress in targeted therapy for non-small cell lung cancer

New Approaches for Individual Treatment of Advanced Non-Small Cell Lung Cancer

Targeted therapies for treatment of non-small cell lung cancer--Recent advances and future perspectives

Therapeutic advances in non‐small cell lung cancer: Focus on clinical development of targeted therapy and immunotherapy

Targeted Therapy for Non-Small-cell Lung Cancer Using EGFR-TKIs

Targeted Therapies for Lung Cancer Beyond Anti-Epidermal Growth Factor Receptors and Anti-Vascular Endothelial Cell Growth Factor Receptors: Exploring a New Frontier

Top advances of the year: Targeted therapy for lung cancer

Medical Treatment of Advanced Non-Small Cell Lung Cancer: Progress in 2014

Molecular pathways, resistance mechanisms and targeted interventions in non-small-cell lung cancer

Annual progress of clinical research on targeted therapy for nonsmall cell lung cancer in 2022

Advancements in NSCLC: From Pathophysiological Insights to Targeted Treatments

New promises and challenges in the treatment of advanced non-small-cell lung cancer

Advancements in NSCLC

Targeted therapy of non-small cell lung cancer: mechanisms and clinical trials

Breakthrough in targeted therapy for non-small cell lung cancer

Update on Targeting EGFR in Advanced Non-Small-cell Lung Cancer

[News about targeted therapies in non-small-cell lung cancer in 2015 (except immuno-therapy)]

The emerging treatment landscape of targeted therapy in non-small-cell lung cancer